Today: 29 April 2026
Browse Category

NYSE:SHAK 6 January 2026 - 25 April 2026

Shake Shack Stock Gets a Fresh Wall Street Boost Before Earnings. Here’s What Changed

Shake Shack Stock Gets a Fresh Wall Street Boost Before Earnings. Here’s What Changed

Guggenheim initiated Shake Shack at Buy with a $120 price target, citing margin upside and expansion potential. Shares rose 5.6% to $103.02. The call comes ahead of Shake Shack’s May 7 earnings report, with recent data showing first-quarter visits up nearly 20% year-over-year. JPMorgan raised its target to $100 but kept a Neutral rating, reflecting mixed analyst sentiment.
25 April 2026
··
Shake Shack Stock Price Falls 4% Despite Bullish $125 Analyst Call

Shake Shack Stock Price Falls 4% Despite Bullish $125 Analyst Call

Shake Shack shares fell 4.4% to $81.32 Friday, outpacing the S&P 500’s 1.7% drop, as oil prices surged and consumer sentiment weakened. D.A. Davidson reiterated a Buy rating and $125 price target, implying 54% upside. Shake Shack reported 15.4% revenue growth in 2025 and plans 55 to 60 new company-operated openings in 2026. The stock closed at about 95 times trailing earnings, far above sector peers.
28 March 2026
··

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 3:00 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop